lood coagulation proceeds by a cascade of sequential proteolytic reactions leading to the formation of a thrombus. ' The physiologically important reaction that initiates this cascade is the binding of the plasma protease factor VII/Vlla to the transmembrane protein tissue factor (TF).2-4 TF is normally present in blood vessel walls separated from factor VII/VIIa by an endothelial cell barrier.5-7 It has been shown in several animal studies that thrombus formation could be induced by disrupting the endothelial barrier. [8] [9] [10] Similarly, thrombosis can be inhibited by blocking TF. 1"-14 In the present study, a rabbit model of thrombosis8 based on the Folts canine model'5 was used to test the hypothesis that activation of the extrinsic coagulation pathway is important in the initiation of intravascular thrombosis. This model was designed to provide condi-abolished, and a steady normal blood flow was restored, indicating that thrombus formation had been blocked by AP-1. By contrast, in all rabbits that received the control monoclonal antibody, CFV continued unaltered. There was no change in the partial thromboplastin time and ex vivo platelet aggregation to several different agonists after infusion of AP-1, indicating an absence of systemic effects on the coagulation process. We conclude that activation of the extrinsic coagulation pathway has a key role in triggering intravascular thrombosis and that an anti-TF monoclonal antibody is an effective antithrombotic agent that could have therapeutic potential for humans. ( Research Inc) in TBS containing 2% bovine serum albumin and 0.2% Tween 20. The bound peroxidase activity was detected using phenylenediamine. 25 Inhibitory activity. The culture media were incubated with RTF (1 ,uL culture media mixed with 1 ng relipidated purified RTF in 100 ,L TBS) at 37°C for 30 minutes, and the inhibition of TF procoagulant activity was measured in a two-stage clotting assay.20 One inhibitory hybridoma, called AP-1, was further expanded, cloned, and stored frozen.
Purification and Characterization of AP-1
Larger quantities of antibody were obtained by production of intraperitoneal tumors in mice that had been primed at least 1 week previously with an intraperitoneal injection of 0.5 mL Pristane (Aldrich). The ascites fluid was centrifuged at 3000g for 15 minutes and filtered through a 0.4-gm filter (Amicon), and the AP-1 was affinity-purified using protein G Sepharose (Pharmacia) and desalted using a PD-10 column (Pharmacia). Protein concentration was determined by a dye-binding assay of Bradford,17 and purity of the protein was assayed by SDS-PAGE.18 IgG subtyping of this clone was carried out using a hybridoma Sub-Isotyping Kit (Calbiochem Corp, La Jolla, Calif).
Endotoxin levels were determined by the limulus amebocyte lysate method using the Etoxate Kit (Sigma Chemical Co, St Louis, Mo) and verified by testing (Associates of Cape Cod, Inc, Woods Hole, Mass). Endotoxin levels of purified AP-1 used in the present study were <0.03 EU/mg.
Rabbit Model of Thrombosis
The rabbit model has been described in detail elsewhere. 8, 26 Briefly, New Zealand White rabbits of either sex were anesthetized with a mixture of ketamine (35 mg/kg) and xylazine (5 mg/kg) administered intramuscularly. Anesthesia was maintained during the course of the experiment by an intravenous infusion of ketamine of sufficient strength to abolish the corneal reflex. Through a median incision of the neck, the left or right common carotid artery was exposed and carefully isolated from the surrounding tissue. Polyethylene catheters were inserted into a jugular vein for drug administration and also into a femoral artery for continuous blood pressure monitoring. A segment of the exposed carotid artery was injured by gently squeezing the artery between a pair of rubber-covered forceps. An external plastic constrictor was placed around the damaged site. Carotid blood flow velocity hours, the animals were reinjected with AP-1 as described above.
Ex Vivo Platelet Aggregation and Prothrombin Time Determination
To determine whether AP-1 affected platelet function per se, the response to several aggregating agents was evaluated ex vivo both before and after administration of the last bolus of AP-1. Fourteen milliliters of blood was drawn into a syringe containing 1.5 mL of 3.8% sodium citrate and centrifuged at 120g for 20 minutes at room temperature to obtain plateletrich plasma (PRP). PRP was removed and recentrifuged at lOOOg for 5 minutes to obtain platelet-poor plasma (PPP). Platelet aggregation was measured turbidimetrically on a Chronolog aggregometer and recorded on a linear recorder. The aggregometer was calibrated by the use of PRP, and the test was performed on 250 ,L PRP in a siliconized cuvette with continuous stirring. The platelet count in the PRP was adjusted to 3 x 10W /4L by dilution with PPP as needed. Aggregation was induced in PRP in response to collagen, ADP, ristocetin, the thromboxane analogue U46619, and arachidonate at various concentrations.
To determine the effect of AP-1 administration on prothrombin time, blood was collected using sodium citrate as an CFV indicates cyclic flow variation; mAb, monoclonal antibody. All rabbits were initially injected with 2.0 mg/kg control mAb. After monitoring the effect of the control mAb, the rabbits were injected with AP-1. Rabbits 1 and 3 received a single injection of 0.05 mg/kg AP-1, and rabbits 2 and 4 received multiple injections up to cumulative doses of 0.15 and 0.2 mg/kg AP-1, respectively. anticoagulant (3.8%) and centrifuged at 2000g for 10 minutes at 4°C to separate the plasma. Prothrombin time was measured before and after each injection of AP-1 using rabbit brain thromboplastin on the Cascade TM 480 (Helena Laboratories, Beaumont, Tex). All assays were performed in duplicate.
Immunostaining of Rabbit Vascular Tissues
Histological examination of the carotid arteries was performed as described by Wilcox et a15 in four additional animals, of which two did not receive any treatment and the other two were administered AP-1. The injured carotid arteries as well as the normal contralateral carotid arteries were dissected and cleaned by brief immersion in phosphate-buffered saline (PBS) and then maintained in 15% sucrose/ isotonic PBS for 6 to 16 hours at 4°C. Tissues were embedded in OCT (methyl methacrylate) compound, quick-frozen in isopentane precooled in liquid nitrogen (-196°C) , and stored at -70°C in airtight bags. Sections (10 ,lm) of the frozen tissues were mounted on polylysine-coated microscope slides and immediately frozen at -70°C.
Immunohistochemistry was performed as follows. Briefly, frozen sections were air-dried for 10 minutes, acetone-treated for 2 minutes, blocked with 10% horse serum for 30 minutes at 37°C, incubated with AP-1 (1 ,ug/mL in 2% horse serum) for 1 hour at 37°C, washed with 3x PBS, incubated with biotinylated anti-mouse IgG (Vectastain ABC kit, Vector Laboratories, Inc, Burlingame, Calif), diluted in 2% horse and 2% rabbit serum for 30 minutes at room temperature, washed with 3 x PBS, incubated with ABC reagent for 30 minutes at room temperature, and color-developed for peroxidase using 0.1% diaminobenzidine tetrahydrochloride in PBS containing 0.5% Triton X-100 and 0.02% H202. Sections were counterstained with hematoxylin, dehydrated in graded ethanols, displaced in xylenes, and mounted with Permount (Fisher Scientific).
Immunohistochemistry of carotid vessels from animals injected with AP-1 was performed as described above except that the first incubation with the primary antibody, AP-1, was omitted.
Statistical Analysis
All values are expressed as mean+SEM. The rate of inhibition of CFV by AP-1 was evaluated by Fisher's extract test. Measurements of hemodynamic variables, platelet aggregation, and prothrombin time were compared before and after administration of AP-1 by one-way ANOVA with a design for repeated measurements, which was followed by Student's t test for paired samples with Bonferroni's correction when an F value was found to be significant. A value of P<.05 defined significant differences between populations.
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80. in normal and injured rabbit carotid artery. The affinity-purified AP-1 (1 gg/mL) was used for immunohistochemical detection of TF. A mouse monoclonal antibody against human TF was used as a control and showed no staining for TF in a normal vessel (a). TF was localized in the adventitia (A) and was not detectable in the media (M) and intima (I) in both normal (b) and injured (c) vessels. T indicates thrombi; L, lumen. Note that in panel c the arrowed portion of the media (M) is relatively well preserved, whereas the media adjacent to the arrowed A is thin and disrupted. At that location (arrowed A) the adventia is exposed to flowing blood.
Results

Preparation and Characterization of an Anti-RTF mAb
The RTF antigen purified from rabbit brain migrated in SDS-polyacrylamide gel as a single 43-kD band that reacted with polyclonal anti-RTF antibodies on a Western blot (data not shown); the specific activity of the purified preparation was 0.5 x 10' U/mg protein. A purified reconstituted human TF preparation was used as a standard in our laboratory and has a specific activity of 1.Ox 10' U/mg protein.
From a total of 900 hybridoma lines generated from mice immunized with the RTF, one was chosen. The antibody produced by this clone, AP-1, was selected because of its potent neutralizing activity against RTF: 8 ng/mL purified AP-1 gave 50Cc inhibition of RTF activity in a two-stage clotting assay (Fig 2) . Effect of AP-1 in Rabbit Model of Thrombosis Recurrent thrombosis was induced in the carotid arteries of nine rabbits by injuring the vessel wall and applying a constrictor at the site of injury. CFV was monitored for 30 minutes to establish a stable baseline. AP-1 was then infused intravenously at an initial dose of 0.05 mg/kg body weight. In five of the nine rabbits, CFV was abolished within 20 minutes after a single injection of this dose of AP-1 (Fig 3) . The other four rabbits, which did not respond to the initial dose of AP-1 received additional doses and also showed inhibition of CFV. The maximum cumulative dose of AP-1 required to restore normal blood flow in all nine rabbits was 1.5 mg/kg (Table 1) . Normal blood flow continued for the duration of the experiment, which was terminated after 2 hours.
A control experiment was performed with an mAb that showed no inhibitory activity in the two-stage coagulation assay against RTF. Injection of this mAb into injured rabbits at the relatively high dose of 2 mg/kg body weight had no effect on CFV, whereas a subsequent injection of AP-1 abolished them (Table 2) . Thus, the antithrombotic effect of AP-1 appears to result from its inhibitory activity against RTF rather than from nonspecific effects.
To test for possible systemic effects of AP-1, which may predispose the rabbit to an increased risk of bleeding, prothrombin times (in seconds) were measured on blood samples obtained before and after injection of AP-1 and were not statistically different (8.0±0 versus 8.4+4 seconds). Thus, the dose of AP-1 sufficient to eliminate CFV in injected rabbits produced no detectable systemic effect on coagulation.
Since it has been shown that inhibition of platelet function usually results in elimination of CFV in this model,8 ex vivo platelet aggregation in response to various agonists was studied in plasma samples obtained from rabbits before and after infusion of AP-1. No differences were observed after the administration of AP-1 in platelet aggregation in response to ADP, collagen, arachidonate, U46619. or ristocetin (Fig 4) . Thus, AP-1 at the dose used in the present study does not affect platelet function.
Immunohistochemical Localization of TF in Rabbit Carotid Vessel Using AP-1 Carotid vessels were studied by immunohistochemistry to map the distribution of RTF in the vessel wall. RTF was found predominantly in the adventitia in both the injured and noninjured blood vessels. TF was not detectable in the intima, including the endothelium, or media of the vessel (Fig 5) . These results are consistent with earlier reports.t-732
In the two animals injected with AP-1 before death, binding of the mAb to TF in the adventitia was seen in both the normal and injured vessels, as demonstrated using peroxidase-labeled anti-mouse antibody (Fig 6), but not in the animals injected with the control antibody. High-power photomicrographs of injured stenosed vessel, stained with Verhoeffs stain for elastic tissue, showed severe disruption of vessel wall (Fig 7) .
Discussion
The present study demonstrates that activation of the extrinsic coagulation pathway plays an important role in the formation of intravascular thrombi and that AP-1, an mAb against rabbit TF, is a potent antithrombotic intervention in this model.
The rabbit model of thrombosis used in the present study is based on a model developed by Folts et al 1 that was originally designed for dogs and later adapted for rabbits.89 This model allows a reproducible pattern of recurrent thrombosis to be established before testing potential antithrombotic agents. A key feature of the model is the provision of an internal control for each animal. The sequential cycles of thrombus formation and dislodgment at the site of induced arterial injury causes CFV, which can be monitored accurately with a Doppler flow probe positioned proximal to the injury. Histological studies on arterial tissue samples27 and studies with radiolabeled platelets28 have demonstrated that the CFV pattern is a reliable indicator of the presence of thrombus at the site of injury.
The agents tested for antithrombotic activity in the present study and in four other animal studiesl '-14 (Table 3) inhibit an early step of the extrinsic coagulation pathway involving the activation of factor X by the TF-factor VII/VIla complex. Inhibition of this step offers two major advantages over blocking later steps in the coagulation pathway. One is that the TF-factor VII/Vila complex is probably formed only at the site of arterial injury, where it remains membrane associated; another is that the coagulation pathway involves a rapidly amplified cascade of proteolytic reactions that would necessitate, at a late step in the cascade, the use of relatively high doses of an antithrombotic agent to exert a significant inhibitory effect. In the present study, which we regard as an extension of those quoted above, conditions were produced to model situations seen clinically. Immunohistochemistry of the rabbit carotid vessels using AP-1 showed extensive staining of TF in the adventitia, consistent with an earlier report." Careful histological examination of samples from the damaged vessels revealed an injury extending to the adventitia in some sections (Figs 5 and  7 ). Therefore, it is possible that adventitial TF was responsible for triggering the extrinsic pathway in this model. Nevertheless, AP-1 was able to block TF-induced thrombosis irrespective of the site and quantity of TF present.
In separate experiments, immunohistochemistry was performed using anti-mouse IgG antibodies to detect AP-1 in injured and noninjured vessels. AP-1 was identified in the adventitia in both vessels of rabbits injected with AP-1 (Fig 6) but not in the rabbits injected with the control antibody. This result suggests that intravenously injected antibody not only blocks the TF in the damaged inner layers but also binds to the adventitial TF. Thus, the intact IgG molecule can infiltrate either through the vasculature or vasa vasorum and reach the target within minutes, thus possibly avoiding the need for local delivery.
The antithrombotic agent used for the present study was AP-1, an mAb that was generated against rabbit TF. AP-1 has a high specific affinity for RTF, and it blocks the extrinsic blood coagulation pathway in an in vitro assay system. It was possible to completely prevent thrombosis in our rabbit model by injecting doses of AP-1 ranging from 0.05 to 1.5 mg/kg, which are considerably lower concentrations than required in earlier studies with a polyclonal anti-RTF antibody'3 or anti-human TF mAbl" (Tables 1 and 3 ). The high potency and specificity of AP-1 probably accounts for its antithrombotic effect in the absence of concomitant systemic effects, as demonstrated by the absence of changes in both prothrombin time and platelet aggregation. Thus, normal hemostasis and platelet function are maintained during the treatment with AP-1 in contrast to the systemic effects seen with TF pathway inhibitor12 and other antiplatelet agents. Even within the low range of the antibody used, there was a 30-fold variation in the dose. This is probably due to the quantity of TF present at the site of injury. Larger quantities of TF require higher doses of the antibody for neutralization. In previous studies,11"12 inhibitory reagents were infused over the duration of the study or before the thrombus had formed. In the present study, AP-1 was injected once a stable baseline thrombus had formed. This strategy of inhibiting thrombi once formed is important for potential clinical applications. The present model more closely mimics conditions seen in humans than the published studies.1"-'4 It was designed to simulate the spontaneous rupture of an atherosclerotic plaque as might occur in patients with unstable angina or myocardial infarction. It is our hypothesis that such vascular injury exposes TF in the subendothelium or even in the adventitia, which then initiates the coagulation cascade. In support of this hypothesis, we were able to block continuing thrombosis in the rabbit at the site of vascular injury by the infusion of the anti-RTF mAb. Previous work by Weiss et al29 supports the hypothesis that subendothelial TF is the essential initiator of thrombus formation in injured blood vessels. Using human umbilical vein segments, they demonstrated that removal of the endothelium is necessary for clotting to occur on the vessel surface and that thrombus formation is blocked by preexposure of the damaged vessel surface to an anti-TF mAb. Although we were unable to detect TF in the subendothelium, intima, or media by immunohistochemical technique, we believe that this was probably due to the lower sensitivity of the detection technique.
To summarize, infusion of low doses of anti-RTF mAb completely inhibited thrombus formation in all rabbits tested without apparent systemic effects. Thus, the administration of a neutralizing anti-TF mAb promises to be an effective antithrombotic strategy in vivo and would be ideal for inhibiting thrombosis in patients with unstable angina. The present study confirms the role of TF in triggering thrombosis via the extrinsic coagulation pathway.
